Mozobil (Plerixafor) for Lymphoma

Overview
Mozobil is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for use before autologous stem cell transplant in people with non-Hodgkin lymphoma and multiple myeloma. Mozobil is used in combination with granulocyte-colony stimulating factor (G-CSF). Mozobil is also referred to by its drug name, plerixafor.

Mozobil is a hematopoietic stem cell mobilizer. Mozobil is believed to work by increasing the amount of hematopoietic (blood forming) stem cells in the blood for collection.

How do I take it?
Prescribing information states that Mozobil is given daily as a subcutaneous injection for up to four consecutive days.

Mozobil comes in the form of a solution in a single-use vial.

Side effects
The FDA-approved label for Mozobil lists common side effects including headache, dizziness, fatigue, joint pain, nausea, diarrhea, vomiting, elevated white blood cell count, low platelet count, and injection site reactions.

Rare but serious side effects listed for Mozobil include hypersensitivity reactions, rupture of the spleen, mobilization of cancer cells out of the bone marrow, and fetal harm in pregnant women.

Notably, Mozobil should not be used in individuals with leukemia.

For more details about this treatment, visit:

Mozobil — Sanofi
https://www.mozobil.com